Top Wall Street analysts changed their outlook on these top names.
For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
Cantor Fitzgerald analyst Kristen Kluska downgraded Monopar Therapeutics Inc (NASDAQ:MNPR) from Overweight to Neutral and raised the price target from $109 to $119.
Monopar Therapeutics closed at $114.90 on Wednesday.
See how other analysts view this stock.






